Abbisko Therapeutics, a Shanghai clinical-stage biopharma, received approval to begin a US Phase I trial for ABSK021, a small molecule CSF-1R inhibitor. By inhibiting CSF-1R, ABSK021 is expected to reprogram tumor-associated macrophages (TAMs) and other immune cells and limit tumor immunosuppression. Abbisko, which discovered the candidate and owns full intellectual property rights globally, believes ABSK021 may prove to be a best-in-class drug. The Phase I trial will test ABSK021 in patients with advanced malignancies and Tenosynovial Giant Cell Tumors (TGCT). Source: China Biotoday
